Glazer Capital LLC’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Glazer Capital LLC’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-145,915	Closed	-$3.37M	–	863
2020 Q4	$3.37M	Buy	+145,915	New	+$1.85M	0.12%	181

Glazer Capital LLC's PRVL Position: Q1 2021 in Review

Glazer Capital LLC sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 145,915 shares — an estimated $3.37M sold.

Glazer Capital LLC first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $3.37M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Glazer Capital LLC reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Glazer Capital LLC sold 145,915 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $3.37M.
Glazer Capital LLC first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Glazer Capital LLC's Prevail Therapeutics Inc. Common Stock position peaked at $3.37M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Glazer Capital LLC's 13F filing for Q1 2021, filed 14 May 2021.